Loading...
In previous studies, combination therapy with an antimuscarinic blocker (tolterodine; Detrol) and an α1-blocking agent (tamsulosin; Flomax) helped men with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (JW Dec 7 2006). Now, in a U.S. multisite study, researchers evaluated another antimuscarinic agent, extended-release oxybutynin (Ditropan and generics), in combination with tamsulosin in 409 men (mean age, 63) who had moderate-to-severe storage LUTS (urgency, frequency, nocturia, urge incontinence, or a combination).
Participants had peak urine flow ≥8 mL/second and post-void residual (PVR) volume <150 mL. All men received daily tamsulosin (0.4 mg) and were randomized to daily extended-release oxybutynin (10 mg) o…